Anti-VEGF Receptor 2抗体(ab39638)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Rat, Human
- Isotype: IgG
概述
-
产品名称
Anti-VEGF Receptor 2抗体
参阅全部 VEGF Receptor 2 一抗 -
描述
兔多克隆抗体to VEGF Receptor 2 -
宿主
Rabbit -
经测试应用
适用于: ICC/IF, WB, IHC-Pmore details -
种属反应性
与反应: Rat, Human
预测可用于: Mouse -
免疫原
The antiserum was produced against synthesized non-phosphopeptide derived from human VEGF Receptor 2 around the phosphorylation site of tyrosine 951.
-
阳性对照
- WB: SK-OV3 cell lysate. IHC-P: Human brain tissue and stomach cancer tissue; Rat spinal cord tissue. ICC/IF: HepG2 cells.
-
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
存储溶液
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg2+ and Ca2+ -
Concentration information loading...
-
纯度
Immunogen affinity purified -
纯化说明
This antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope specific immunogen. -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab39638于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
ICC/IF | (1) |
Use a concentration of 1 µg/ml.
|
WB | (1) |
1/500 - 1/1000. Predicted molecular weight: 151 kDa.
|
IHC-P | (1) |
1/50 - 1/100.
|
说明 |
---|
ICC/IF
Use a concentration of 1 µg/ml. |
WB
1/500 - 1/1000. Predicted molecular weight: 151 kDa. |
IHC-P
1/50 - 1/100. |
靶标
-
功能
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
疾病相关
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
序列相似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻译后修饰
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
细胞定位
Membrane. - Information by UniProt
-
数据库链接
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
see all -
别名
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
图片
-
Western blot analysis of extracts from SK-OV3 cells using VEGF Receptor 2 antibody ab39638 (Lane 1 and 2) and VEGF Receptor 2 (phospho-Tyr951) antibody (Lane 3 and 4).
Secondary antibody - anti-rabbit HRP (ab6721)
-
Immunohistochemical analysis of human brain tissue stained with ab39638. The image on the right is blocked with the synthesized peptide.
-
Immunohistochemical analysis of human stomach cancer tissue stained with ab39638 at 1/200 dilution at 4oC overnight. The negative control was secondary antibody only.
-
Immunohistochemical analysis of rat spinal cord tissue stained with ab39638 at 1/200 dilution at 4oC overnight. The negative control was secondary antibody only.
-
ICC/IF image of ab39638 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab39638, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
-
Anti-VEGF Receptor 2 antibody (ab39638) (Anti-VEGF Receptor 2 antibody) + HeLa cell lysate
Predicted band size: 151 kDa
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (21)
ab39638 被引用在 21 文献中.
- Ma C et al. Curcumol repressed cell proliferation and angiogenesis via SP1/mir-125b-5p/VEGFA axis in non-small cell lung cancer. Front Pharmacol 13:1044115 (2022). PubMed: 36467048
- Luo Y et al. Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway. Front Mol Biosci 8:652443 (2021). PubMed: 34746227
- Gehmeyr J et al. Disabling VEGF-Response of Purkinje Cells by Downregulation of KDR via miRNA-204-5p. Int J Mol Sci 22:N/A (2021). PubMed: 33671638
- Qian JJ et al. Expression of VEGF-A Signaling Pathway in Cartilage of ACLT-induced Osteoarthritis Mouse Model. J Orthop Surg Res 16:379 (2021). PubMed: 34127028
- Zhou BY et al. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin 41:1234-1245 (2020). PubMed: 32327724